The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Path: ILD with a granulomatous component (see also Im)
Publications
Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis.
The American journal of surgical pathology 2019 Oct;43;1331-1340 — 2019 Oct — 1331-1340
Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 08;13;1076-1082 — 2018 08 — 1076-1082
Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event.
Cancer immunology research 2018 06;6;630-635 — 2018 06 — 630-635
Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Mar;35;709-717 — 2017 Mar — 709-717